Milestone Pharmaceuticals Collaborates with Arrhythmia Alliance on SVT Awareness

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a company dedicated to developing cardiovascular treatments, has announced a collaboration with Arrhythmia Alliance to increase public awareness about supraventricular tachycardia (SVT). This partnership will center around SVT Awareness Day, which will be observed on Wednesday, June 5, 2024, during World Heart Rhythm Week from June 4-10.

SVT is a type of arrhythmia characterized by rapid heartbeats, causing symptoms such as palpitations, shortness of breath, and anxiety. In extreme cases, the heart rate can surge up to 250 beats per minute, far exceeding the normal range of 60 to 100 beats per minute for an average adult. The event aims to shed light on the condition, which affects an estimated two million people in the United States.

Joseph Oliveto, President and CEO of Milestone Pharmaceuticals, expressed the company’s enthusiasm for the initiative, highlighting its alignment with their mission to improve the lives of patients with complex cardiovascular conditions. He acknowledged the important contributions of the Arrhythmia Alliance in providing educational resources to support SVT patients.

To support SVT Awareness Day, Arrhythmia Alliance and its partners have developed several resources and activities for those affected by the condition. These include virtual coffee mornings, Live X Chats, and educational sessions on Facebook Live. These initiatives aim to facilitate awareness, encourage people to seek medical advice, and explore treatment options.

Key activities planned for the awareness campaign include:
- A Live X Chat on Tuesday, June 4 at 11 am EDT.
- A Facebook Live Chat with Dr. James Ip from Weill Cornell Medical Center on Thursday, June 6 at 11 am EDT.
- SVT Coffee Morning Chats scheduled for Wednesday, June 5 at 11 am EDT and Friday, June 7 at 11 am BST.

SVT episodes, which can last from a few minutes to several hours, often disrupt daily activities due to their unpredictable nature. Symptoms include severe palpitations, breathlessness, dizziness, and chest discomfort. The condition can be particularly debilitating for patients with existing cardiovascular issues such as heart failure or coronary disease. Diagnosing SVT is often challenging due to its episodic nature, making it difficult to capture the irregular heart rhythm on an electrocardiogram unless an episode is occurring.

Many healthcare providers are frustrated with the limited treatment options available. Current treatments often require emergency department visits or invasive procedures like cardiac ablation. Despite treatment, some patients continue to experience symptoms or cannot tolerate the side effects of medications.

Milestone Pharmaceuticals offers additional information through their resource, SVT Heart to Heart, which is designed to support patients in managing their condition.

Arrhythmia Alliance is a coalition dedicated to those affected by cardiac arrhythmias, including patients, caregivers, healthcare professionals, and policymakers. The organization works to raise awareness and provide resources for various heart rhythm disorders.

Milestone Pharmaceuticals, a biopharmaceutical firm, is focused on innovative solutions for cardiovascular diseases. The company is currently developing etripamil, a nasal spray that patients can self-administer to manage episodic attacks associated with PSVT and AFib-RVR without the need for medical supervision.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!